Categories: News

Biotricity to Discuss Sales Expansion, Recent Financing, and Wearable Medical Device Portfolio Expansion at H.C. Wainwright Conference

Company’s Momentum Continuing with Sales Growth, Recent Nasdaq listing and Successful Equity Raise

REDWOOD CITY, CA / ACCESSWIRE / September 8, 2021 / Biotricity, Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today reported its CEO Waqaas Al-Siddiq is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be available on-demand starting at 7:00 a.m. ET on Monday, September 13, 2021 (details provided below).

Dr. Al-Siddiq will discuss the Company’s continuing sales growth of its FDA-approved Bioflux® mobile cardiac telemetry (MCT) device which, as the Company previously announced, drove its FY22-1Q revenue up 290% YOY and approximately 49% sequentially. He will also discuss sales expansion and the company’s planned product portfolio that the Company believes will increase the current total addressable market (TAM) while growing revenues. As previously announced, Biotricity recently completed a $15 million equity raise and listed on the Nasdaq Capital Market.

The presentation will be available to registered attendees from Monday, September 13 to Wednesday, September 15. To access the presentation, investors may register for the conference here. During the conference, the management team will also be available for virtual one-on-one meetings with registered attendees.

A live webcast of the conference call can be accessed by clicking on the following link: Webcast Audio will stream through your selected device. A full replay of the presentation will be available at the same link shortly after the conclusion of the live presentation and will be available for 90 days.

About Biotricity Inc.
Biotricity (NASDAQ:BTCY) is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Contacts:
Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com

Todd Kehrli or Mark Forney
MKR Investor Relations, Inc.
btcy@mkr-group.com

Media Contact:
Bospar
prforbiotricity@bospar.com

SOURCE: Biotricity, Inc.

View source version on accesswire.com:
https://www.accesswire.com/663132/Biotricity-to-Discuss-Sales-Expansion-Recent-Financing-and-Wearable-Medical-Device-Portfolio-Expansion-at-HC-Wainwright-Conference

Staff

Recent Posts

71 Remote Patient Monitoring Companies Earn Highest Certification for Healthcare Excellence from Smart Meter in 2023

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, the number one supplier of Cellular Remote Patient Monitoring (RPM)™, has…

3 hours ago

NextGen Healthcare Launches AI-Driven Efficiency Solution for Mental and Behavioral Health Professionals

Company to Showcase NextGen® Ambient Assist for Behavioral Health April 15-17 at NatCon 2024REMOTE-FIRST COMPANY/ST.…

3 hours ago

Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users’ Summit

Shaping the Future of Aesthetic Treatments with Advanced Medical TechnologyCLEARWATER, Fla.--(BUSINESS WIRE)--Apyx® Medical Corporation (NASDAQ:APYX)…

3 hours ago

VitalHub Corp. Closes $40.25 Million Bought Deal Public Offering with Full Exercise of Over-Allotment Option

Toronto, Ontario--(Newsfile Corp. - April 11, 2024) - VitalHub Corp. (TSX: VHI) (the "Company" or…

3 hours ago

Akanda Corp. Announces Closing of the Sale of RPK

London, United Kingdom--(Newsfile Corp. - April 11, 2024) - On April 1, 2024, Akanda Corp.…

3 hours ago

Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB(R) at NATA24 Annual Symposium

HENNINGSDORF, GERMANY / ACCESSWIRE / April 11, 2024 / Lindis Blood Care, a company aiming…

3 hours ago